| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (T...
 
																	TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This ...
 
																	
 
																	HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price ...
 
																	TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(...
 
																	 
																	
 
																	Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9 price target.
 
																	Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lowers the price target from ...